101
|
Luo X, Yang L, Xiao L, Xia X, Dong X, Zhong J, Liu Y, Li N, Chen L, Li H, Li W, Liu W, Yu X, Chen H, Tang M, Weng X, Yi W, Bode A, Dong Z, Liu J, Cao Y. Grifolin directly targets ERK1/2 to epigenetically suppress cancer cell metastasis. Oncotarget 2016; 6:42704-16. [PMID: 26516701 PMCID: PMC4767464 DOI: 10.18632/oncotarget.5678] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2015] [Accepted: 10/14/2015] [Indexed: 12/13/2022] Open
Abstract
Grifolin, a secondary metabolite isolated from the fresh fruiting bodies of the mushroom Albatrellus confluens, has been reported by us and others to display potent antitumor effects. However, the molecular target of grifolin has not been identified and the underlying mechanism of action is not fully understood. Here, we report that the ERK1/2 protein kinases are direct molecular targets of grifolin. Molecular modeling, affinity chromatography and fluorescence quenching analyses showed that grifolin directly binds to ERK1/2. And in vitro and ex vivo kinase assay data further demonstrated that grifolin inhibited the kinase activities of ERK1/2. We found that grifolin suppressed adhesion, migration and invasion of high-metastatic cancer cells. The inhibitory effect of grifolin against tumor metastasis was further confirmed in a metastatic mouse model. We found that grifolin decreased phosphorylation of Elk1 at Ser383, and the protein as well as the mRNA level of DNMT1 was also down-regulated. By luciferase reporter and ChIP assay analyses, we confirmed that grifolin inhibited the transcription activity of Elk1 as well as its binding to the dnmt1 promoter region. Moreover, we report that significant increases in the mRNA levels of Timp2 and pten were induced by grifolin. Thus, our data suggest that grifolin exerts its anti-tumor activity by epigenetic reactivation of metastasis inhibitory-related genes through ERK1/2-Elk1-DNMT1 signaling. Grifolin may represent a promising therapeutic lead compound for intervention of cancer metastasis, and it may also be useful as an ERK1/2 kinase inhibitor as well as an epigenetic agent to further our understanding of DNMT1 function.
Collapse
Affiliation(s)
- Xiangjian Luo
- Cancer Research Institute, Key laboratory of Chinese Ministry of Education, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, PR China.,Molecular Imaging Center, Xiangya Hospital, Central South University, Changsha, Hunan 410078, PR China
| | - Lifang Yang
- Cancer Research Institute, Key laboratory of Chinese Ministry of Education, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, PR China.,Molecular Imaging Center, Xiangya Hospital, Central South University, Changsha, Hunan 410078, PR China
| | - Lanbo Xiao
- Cancer Research Institute, Key laboratory of Chinese Ministry of Education, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, PR China
| | - Xiaofeng Xia
- Department of Systems Medicine and Bioengineering, Houston Methodist Research Institute, Houston, TX 77030, USA
| | - Xin Dong
- Cancer Research Institute, Key laboratory of Chinese Ministry of Education, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, PR China
| | - Juanfang Zhong
- Cancer Research Institute, Key laboratory of Chinese Ministry of Education, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, PR China
| | - Ying Liu
- Cancer Research Institute, Key laboratory of Chinese Ministry of Education, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, PR China
| | - Namei Li
- Cancer Research Institute, Key laboratory of Chinese Ministry of Education, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, PR China
| | - Ling Chen
- Cancer Research Institute, Key laboratory of Chinese Ministry of Education, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, PR China
| | - Hongde Li
- Cancer Research Institute, Key laboratory of Chinese Ministry of Education, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, PR China
| | - Wei Li
- Cancer Research Institute, Key laboratory of Chinese Ministry of Education, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, PR China
| | - Wenbin Liu
- Cancer Research Institute, Key laboratory of Chinese Ministry of Education, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, PR China
| | - Xinfang Yu
- Cancer Research Institute, Key laboratory of Chinese Ministry of Education, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, PR China
| | - Hanyong Chen
- The Hormel Institute, University of Minnesota, Austin, MN 55912, USA
| | - Min Tang
- Cancer Research Institute, Key laboratory of Chinese Ministry of Education, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, PR China
| | - Xinxian Weng
- Cancer Research Institute, Key laboratory of Chinese Ministry of Education, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, PR China
| | - Wei Yi
- Cancer Research Institute, Key laboratory of Chinese Ministry of Education, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, PR China
| | - Ann Bode
- The Hormel Institute, University of Minnesota, Austin, MN 55912, USA
| | - Zigang Dong
- The Hormel Institute, University of Minnesota, Austin, MN 55912, USA
| | - Jikai Liu
- State Key Laboratory of Phytochemistry and Plant Resource in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650204, PR China
| | - Ya Cao
- Cancer Research Institute, Key laboratory of Chinese Ministry of Education, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, PR China.,Molecular Imaging Center, Xiangya Hospital, Central South University, Changsha, Hunan 410078, PR China
| |
Collapse
|
102
|
Shankar E, Kanwal R, Candamo M, Gupta S. Dietary phytochemicals as epigenetic modifiers in cancer: Promise and challenges. Semin Cancer Biol 2016; 40-41:82-99. [PMID: 27117759 DOI: 10.1016/j.semcancer.2016.04.002] [Citation(s) in RCA: 92] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Revised: 04/08/2016] [Accepted: 04/18/2016] [Indexed: 12/21/2022]
Abstract
The influence of diet and environment on human health has been known since ages. Plant-derived natural bioactive compounds (phytochemicals) have acquired an important role in human diet as potent antioxidants and cancer chemopreventive agents. In past few decades, the role of epigenetic alterations such as DNA methylation, histone modifications and non-coding RNAs in the regulation of mammalian genome have been comprehensively addressed. Although the effects of dietary phytochemicals on gene expression and signaling pathways have been widely studied in cancer, the impact of these dietary compounds on mammalian epigenome is rapidly emerging. The present review outlines the role of different epigenetic mechanisms in the regulation and maintenance of mammalian genome and focuses on the role of dietary phytochemicals as epigenetic modifiers in cancer. Above all, the review focuses on summarizing the progress made thus far in cancer chemoprevention with dietary phytochemicals, the heightened interest and challenges in the future.
Collapse
Affiliation(s)
- Eswar Shankar
- Department of Urology, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH 44106, USA; Department of Urology, Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH 44106, USA
| | - Rajnee Kanwal
- Department of Urology, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH 44106, USA; Department of Urology, Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH 44106, USA
| | - Mario Candamo
- Department of Biology, School of Undergraduate Studies, Case Western Reserve University, Cleveland, OH 44106, USA
| | - Sanjay Gupta
- Department of Urology, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH 44106, USA; Department of Urology, Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH 44106, USA; Department of Nutrition, Case Western Reserve University, Cleveland, OH 44106, USA; Division of General Medical Sciences, Case Comprehensive Cancer Center, Cleveland, OH 44106, USA.
| |
Collapse
|
105
|
Song S, Wang Y, Xu P, Yang R, Ma Z, Liang S, Zhang G. The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma. Int J Oncol 2015; 47:1819-28. [PMID: 26412386 DOI: 10.3892/ijo.2015.3182] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2015] [Accepted: 09/03/2015] [Indexed: 11/06/2022] Open
Abstract
Histone deacetylase 8 (HDAC8), a unique member of class I HDACs, shows remarkable correlation with advanced disease stage. The depletion of HDAC8 leads to inhibition of proliferation, apoptosis and cell cycle arrest in multiple malignant tumors. However, little is known about the contribution of HDAC8 to the tumorigenesis of gastric cancer (GC). The present study investigated expression of HDAC8 in GC cell lines and tissues, and the roles of HDAC8 inhibition in the proliferation, cell cycle and apoptosis of gastric cancer cells and explored the potential mechanisms. In the present study, quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR), western blotting, and immunohistochemistry were used to examine the mRNA and protein expression of HDAC8 in GC cell lines and tissues. Then, the correlation between the clinicopathological parameters and the expression of HDAC8 was assessed. Finally, siRNA transfection and HDAC8 plasmid was performed to explore the functions of HDAC8 in GC progression in vitro. We found that the expression of HDAC8 was significantly upregulated both in GC cell lines and tumor tissues compared to human normal gastric epithelial cell, GES-1 and matched non-tumor tissues. Furthermore, depletion of HDAC8 remarkably inhibited GC cell proliferation, increased the apoptosis rate and G0/G1 phase percentage in vitro. Western blotting showed that the expression of protein promoting apoptosis such as, Bmf, activated caspase-3, caspase-6 were elevated following HDAC8 depletion. Our data exhibited an important role of HDAC8 in promoting gastric cancer tumorigenesis and identify this HDAC8 as a potential therapeutic target for the treatment of gastric cancer.
Collapse
Affiliation(s)
- Shiyuan Song
- Department of Oncology, Τhe First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China
| | - Ying Wang
- Department of Oncology, Τhe First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China
| | - Po Xu
- Department of Urology, Τhe First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China
| | - Ruina Yang
- Department of Oncology, Τhe First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China
| | - Zhikun Ma
- Department of Oncology, Τhe First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China
| | - Shuo Liang
- Department of Oncology, Τhe First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China
| | - Guangping Zhang
- Department of Oncology, Τhe First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China
| |
Collapse
|